Heather McArthur, MD, MPH, UT Southwestern Medical Center, Dallas, TX, discusses management strategies for adverse events resulting from antibody-drug conjugates (ADCs) in patients with breast cancer. Whilst interstitial lung disease can be detected radiographically, early detection is crucial, since only patients with grade 1 interstitial lung disease can be rechallenged. Ocular toxicity, mucositis and stomatitis are additional toxicities, where patients receiving datopotamab deruxtecan, a TROP-2-directed ADC, must additionally have prophylactic mouthwash. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
